Endo International (English Wikipedia)

Analysis of information sources in references of the Wikipedia article "Endo International" in English language version.

refsWebsite
Global rank English rank
49th place
47th place
1st place
1st place
1,227th place
684th place
low place
8,921st place
7th place
7th place
99th place
77th place
low place
low place
low place
low place
low place
low place
79th place
65th place
3,281st place
1,880th place
210th place
157th place
407th place
241st place
54th place
48th place
low place
low place
low place
low place
220th place
155th place
5th place
5th place
low place
6,625th place
310th place
208th place
3,796th place
2,268th place
low place
low place
92nd place
72nd place
3,174th place
2,751st place
447th place
338th place
8,771st place
5,253rd place
low place
low place
108th place
80th place
918th place
556th place
2,008th place
1,197th place
low place
6,795th place

bizjournals.com (Global: 407th place; English: 241st place)

bloomberg.com (Global: 99th place; English: 77th place)

  • "Tracking Tax Runaways". Bloomberg News. 1 March 2017. Corporate Expatriates: See the Data. Retrieved 4 February 2023.
  • "Endo Sets Aside $775 Million to Settle Remaining Mesh Lawsuits". Bloomberg.com. 2017-08-07. Retrieved 2023-10-01.
  • "Endo, Glaxo to Settle Suits Over Testosterone Drug". Bloomberg.com. 2018-02-23. Archived from the original on 2018-02-23. Retrieved 2023-10-01.

boston.com (Global: 310th place; English: 208th place)

cbsnews.com (Global: 108th place; English: 80th place)

cnbc.com (Global: 220th place; English: 155th place)

corporate-ir.net (Global: 3,174th place; English: 2,751st place)

phx.corporate-ir.net

delawarebusinesstimes.com (Global: low place; English: low place)

drugwatch.com (Global: low place; English: low place)

endo.com (Global: low place; English: low place)

investor.endo.com

fda.gov (Global: 447th place; English: 338th place)

fiercepharma.com (Global: low place; English: 8,921st place)

forbes.com (Global: 54th place; English: 48th place)

ft.com (Global: 210th place; English: 157th place)

ftc.gov (Global: 3,796th place; English: 2,268th place)

genengnews.com (Global: low place; English: 6,625th place)

inquirer.com (Global: 1,227th place; English: 684th place)

justice.gov (Global: 918th place; English: 556th place)

marketplace.org (Global: low place; English: 6,795th place)

motherjones.com (Global: 2,008th place; English: 1,197th place)

naag.org (Global: low place; English: low place)

npr.org (Global: 92nd place; English: 72nd place)

nytimes.com (Global: 7th place; English: 7th place)

nytimes.com

dealbook.nytimes.com

pharmaceutical-technology.com (Global: low place; English: low place)

pharmaphorum.com (Global: low place; English: low place)

propublica.org (Global: 3,281st place; English: 1,880th place)

reuters.com (Global: 49th place; English: 47th place)

statnews.com (Global: 8,771st place; English: 5,253rd place)

thepharmaletter.com (Global: low place; English: low place)

web.archive.org (Global: 1st place; English: 1st place)

worldcat.org (Global: 5th place; English: 5th place)

search.worldcat.org

wsj.com (Global: 79th place; English: 65th place)

  • Rubin, Ben Fox (5 November 2013). "Endo Health to Buy Paladin Labs for $1.6 Billion". The Wall Street Journal.
  • Liz Hoffman (7 July 2015). "The Tax Inversion Wave Keeps Rolling". The Wall Street Journal. Horizon and other inverted companies are using their new, lower tax rates to turbocharge corporate takeovers. Applying those rates, often in the midteens, to profits of companies in the U.S., with a federal corporate rate of 35%, can yield extra savings on top of those traditionally wrung from mergers. Moreover, unlike the U.S., Ireland and most other countries, only tax profits earned in-country, giving companies the freedom and incentive to shift income to still-lower-tax jurisdictions.